CELF1通过抑制CDKN1B促进胶质瘤细胞增殖的研究

临床肿瘤学杂志 ›› 2018, Vol. 23 ›› Issue (9): 801-805.

CELF1通过抑制CDKN1B促进胶质瘤细胞增殖的研究

1 471000 河南洛阳河南科技大学第一附属医院神经外科

2 450007 解放军第153中心医院病理科

收稿日期:2018-06-27 修回日期:2018-07-11 出版日期:2018-09-30 发布日期:2018-11-28
通讯作者: 赵伟 E-mail:ZW15938796039@163.com

CELF1 promotes proliferation of glioma by inhibiting CDKN1B

Department of Neurosurgery， the First Affiliated Hospital of Henan University of Science and Technology， Zhengzhou 471000， China

Received:2018-06-27 Revised:2018-07-11 Online:2018-09-30 Published:2018-11-28
Contact: ZHAO Wei E-mail:ZW15938796039@163.com

摘要/Abstract

摘要： 目的探讨CELF1在胶质瘤细胞增殖中的作用及可能机制。方法采用实时荧光定量PCR（QPCR）和Western blotting检测胶质瘤细胞系U87、U251、SHG44以及人正常星形胶质细胞系HA1800中CELF1 mRNA和蛋白表达；无义核酸NC（NC组）、siCELF1（siCELF1组）和siCELF1＆siCDKN1B（siCELF1＆siCDKN1B组）转染U87细胞， CCK-8法检测细胞活力，流式细胞术检测细胞周期变化；Western blotting检测CELF1、CDKN1B和Cyclin D1蛋白表达。结果胶质瘤细胞系U87、U251和SHG44 中CELF1 mRNA相对表达量分别为3.1±0.074、4.2±0.137和3.6±0.023，均高于人正常星形胶质细胞HA 1800的1.1±0.054，差异均有统计学意义（P＜0.05）。Western blotting检测CELF1的蛋白表达与mRNA表达一致。沉默CELF1能显著降低U87细胞活力，siCELF1组G0／G1期细胞比例为（63.5±1.33）％，显著高于NC组的（39.4±1.24）％，而siCELF1组S期细胞比例为（14.3±0.095）％，显著低于NC组的（22.8±1.97）％（P＜0.05）。siCELF1组CDKN1B蛋白相对表达量为2.37±0.088，显著低于NC组的1.17±0.101（P＜0.05）。siCELF1组 Cyclin D1蛋白相对表达量为0.274±0.039，显著低于siCELF1＆siCDKN1B组的0.83±0.071（P＜0.05）。siCELF1＆siCDKN1B组细胞活力高于siCELF1组（P＜0.05）。siCELF1＆siCDKN1B组G0／G1期细胞比例为（42.1±1.76）％，显著低于siCELF1组的（62.4±1.92）％（P＜0.05）；而siCELF1＆siCDKN1B组S期细胞比例为（20.3±0.077）％，与NC组的（22.8±1.97）％差异无统计学意义。结论 CELF1通过抑制CDKN1B，进而介导Cyclin D1表达促进胶质瘤细胞增殖。

关键词: 胶质瘤, CELF1, CDKN1B, Cyclin D1, 增殖

Abstract: Objective To investigate the role and possible mechanism of CELF1 in the proliferation of glioma cells. Methods CELF1 mRNA and protein expression in glioma cell lines U87， U251， SHG44 and human normal astrocyte line HA1800 was detected by fluorescence quantitative PCR （QPCR） and Western blotting. U87 cells were transfected with nonsense nucleic acid NC （NC group）， siCELF1 （siCELF1 group） and siCELF1＆siCDKN1B （siCELF1＆siCDKN1B group）. Cell viability was detected by CCK-8 assay， and cell cycle changes were detected by flow cytometry. The protein expression of CELF1， CDKN1B and Cyclin D1 was detected by Western blotting. Results The relative expression levels of CELF1 mRNA in glioma cell lines U87， U25 1 and SHG44 were 3.1±0.074， 4.2±0.137 and 3.6±0.023， respectively， which were higher than those in normal astrocyte line HA 1800， and the differences were statistically significant （P＜0.05）. The protein expression of CELF1 detected by Western blotting was consistent with that of mRNA. Silence CELF1 can significantly reduce U87 cell viability. The proportion of G0／G1 phase cells in siCELF1 group was （63.5±1.33）％， significantly higher than that in NC group （39.4±1.24）％；while proportion of S phase cells in siCELF1 group was （14.3±0.095）％， significantly lower than that in NC group （22.8±1.97）％（P＜0.05）. The relative expression of CDKN1B protein in group siCELF1 was 2.37±0.088， which was significantly lower than that in NC group （P＜0.05）. The relative expression of Cyclin D1 protein in group siCELF1 was 0.274±0.039， which was significantly lower than that in siCELF1＆siCDKN1B group （P＜0.05）. Cell viability in group siCELF1＆siCDKN1B was higher than that in group siCELF1 （P＜0.05）. The proportion of G0／G1 phase cells in siCELF1-siCDKN1B group was （42.1±1.76）％， significantly lower than that in siCELF1 group （62.4±1.92）％（P＜0.05）， while the proportion of S phase cells in siCELF1-siCDKN1B group was （20.3±0.077）％， which was not significantly different from that in NC group （22.8±1.97）％. Conclusion CELF1 mediates the expression of Cyclin D1 by inhibiting CDKN1B， and promotes glioma proliferation.

Key words: Glioma, CELF1, CDKN1B, Cyclin D1, Proliferation

杨晋生, 古选民, 方军超, 赵伟.

CELF1通过抑制CDKN1B促进胶质瘤细胞增殖的研究 [J]. 临床肿瘤学杂志, 2018, 23(9): 801-805.

YANG Jinsheng, GU Xuanmin, FANG Junchao, ZHAO Wei..

CELF1 promotes proliferation of glioma by inhibiting CDKN1B [J]. Chinese Clinical Oncology, 2018, 23(9): 801-805.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

本文评价

推荐阅读 10

[1]	刘锦；李贵新；马传香. 恶性黑色素瘤腹腔转移１例[J]. 临床肿瘤学杂志, 2009, 14(1): 96 .
[2]	石　玮¹，华海清²，王兴华¹. 放疗对肠屏障功能的影响及研究进展[J]. 临床肿瘤学杂志, 2009, 14(1): 89 .
[3]	王杰军，李　睿. ＮＣＣＮ成人癌痛临床实践指南解读[J]. 临床肿瘤学杂志, 2009, 14(1): 80 .
[4]	崔传亮，迟志宏，袁香庆，斯　璐，盛锡楠，郭　军. 重组人血管内皮抑制素联合化疗一线治疗晚期黑色素瘤的Ⅱ期临床研究[J]. 临床肿瘤学杂志, 2009, 14(1): 74 .
[5]	白秀丽¹，马振刚¹，李际君². 紫杉醇联合卡培他滨治疗进展期胃癌的临床观察[J]. 临床肿瘤学杂志, 2009, 14(1): 68 .
[6]	徐卫国¹，杨小青²，郝世柱¹，宋纪宁¹，张鹏东¹，胡潺潺¹，王文雅¹. 大肠癌组织中Ｎｅｕｒｏｐｉｌｉｎ-１的表达及其与肿瘤血管生成的相关性研究[J]. 临床肿瘤学杂志, 2009, 14(1): 29 .
[7]	许景艳¹，欧阳建^１，章宜芬²，周荣富¹，陈　兵¹，张启国¹，杨永公¹，邵小雁¹，徐　勇¹，关朝阳¹. 原发性肋骨血管肉瘤的诊治探讨[J]. 临床肿瘤学杂志, 2009, 14(1): 70 .
[8]	张艳玲，邹　岚，肖　红，黄海辉，谭崇富，阮志华，王　希，梁后杰，庞学利. 影像引导调强放射治疗鼻咽癌[J]. 临床肿瘤学杂志, 2009, 14(1): 51 .
[9]	翟云芝¹，陈振东²，秦凤展¹. Ｅｚｒｉｎ和ＡＫＴ２在大肠癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 25 .
[10]	张　宾¹，李　畅¹，种道群¹，郭永立¹，陈文明¹，王家富². ＰＴＥＮ和ＢＡＧ-１蛋白在子宫内膜样腺癌组织中的表达及其临床意义[J]. 临床肿瘤学杂志, 2009, 14(1): 34 .